A Metabonomics Profiling Study on Phlegm Syndrome and Blood-Stasis Syndrome in Coronary Heart Disease Patients Using Liquid Chromatography/Quadrupole Time-of-Flight Mass Spectrometry

Table 4

Plasma metabolites for discriminating CHD patients from healthy controls.

Mode	RT	Mass	Metabolite	VIP	𝑃	^aFold
EIS^+	6.21	542.28	Cortolone-3-glucuronide	1.75	7.02𝐸−44	−25.59
	5.74	431.21	17-Phenoxy trinor PGF2𝛼 ethyl amide	1.74	1.59𝐸−37	−25.32
	5.71	562.37	Cholesterol glucuronide	1.74	1.34𝐸−35	−25.35
	5.03	362.22	Cortisol	1.73	7.10𝐸−34	−24.65
	7.52	890.51	Dipalmitoyl phosphatidylinositol 3-phosphate	1.73	1.28𝐸−33	−25.53
	15.91	370.24	TXB2	1.73	3.64𝐸−31	−24.54
	13.41	393.3	PGH2-EA	1.71	2.30𝐸−28	−25.08
	15.90	298.18	13,14-Dihydro-15-keto-tetranor PGE2	1.70	5.56𝐸−27	−25.84
	15.90	372.25	TXB1	1.70	1.42𝐸−26	−26.76
	11.98	338.17	18-Carboxy dinor leukotriene B4	1.70	1.55𝐸−26	−24.83
	8.98	413.26	15-Keto-17-phenyl trinor Prostaglandin F2α ethyl amide	1.66	8.12𝐸−22	−24.57
	14.52	510.28	Leukotriene D4 methyl ester	1.65	8.28𝐸−21	−22.56
	6.71	427.27	17-Phenyl trinor prostaglandin F2α Cyclopropyl amide	1.61	1.41𝐸−18	−24.27
	16.05	348.23	PGA2 methyl ester	1.59	2.34𝐸−17	−22.23
	5.77	472.24	Chenodeoxycholic acid 3-sulfate	1.50	1.24𝐸−13	−23.70
EIS^−	1.03	244.07	Uridine	1.98	7.81𝐸−12	−0.72
	16.61	348.23	PGA2 methyl ester	1.98	9.09𝐸−12	3.52
	1.02	136.04	Hypoxanthine	1.90	1.66𝐸−10	−1.84
	1.03	192.03	Citric acid	1.89	2.40𝐸−10	2.12
	3.81	204.09	L-Tryptophan	1.88	3.85𝐸−10	−1.01
	3.81	324.03	Uridine monophosphate (UMP)	1.81	3.09𝐸−09	−1.98
	2.00	165.08	L-Phenylalanine	1.61	5.73𝐸−07	−1.30
	4.66	282.11	2-Aminoadenosine	1.56	1.57𝐸−06	−2.41
	13.16	625.30	Leukotriene C4	1.55	1.83𝐸−06	−2.20
	16.62	302.22	EPA	1.55	1.87𝐸−06	−2.47
	16.88	336.23	LTB4	1.53	2.68𝐸−06	4.50
	1.91	116.05	2-Keto valeric acid	1.51	4.25𝐸−06	−2.05

aFold = log₂(average peak intensity of CHD group/average peak intensity of healthy group), “−” represented downregulated compared to healthy group, and “+” represented upregulated compared to healthy group.